Summary
A bioRxiv preprint reports SPEAR, a method combining laser microdissection and mass spectrometry to measure RNA modifications in small regions of preserved tissue. In human diffuse glioma samples, the authors found lower levels of several methylated RNA modifications in higher-grade foci than in low-grade regions.
Researchers have introduced SPEAR, a workflow for measuring RNA modifications in small, anatomically selected regions of preserved tissue. In a bioRxiv preprint, the team reports that applying it to human diffuse gliomas revealed lower levels of multiple methylated RNA modifications in higher-grade tumour foci than in low-grade regions from the same specimens. The changes were localised and, the authors report, were obscured when tissue was analysed in bulk.
How SPEAR profiles tissue
SPEAR combines laser microdissection with a redesigned liquid chromatography–tandem mass spectrometry (LC-MS/MS) workflow. Laser microdissection isolates chosen areas from a tissue section; LC-MS/MS then separates and measures molecules in the collected material. The method was designed for formalin-fixed, paraffin-embedded (FFPE) tissue, a preserved form used in clinical tissue collections.
The authors report reproducible detection of dozens of RNA modifications in regions as small as 0.1 mm². RNA modifications are chemical changes to RNA molecules. Measuring them across an entire homogenised tissue sample can combine signals from different cell types and tissue regions, making a local change harder to distinguish. SPEAR is intended to retain that spatial information while using mass spectrometry to profile many modifications.
The team first applied the workflow to serial mouse brain sections. It distinguished epitranscriptomic profiles in white matter and gray matter, which the authors used to assess the method’s spatial resolution and reproducibility in a controlled setting.
Local changes in glioma samples
The researchers then analysed human diffuse gliomas containing both low-grade tumour regions and discrete areas undergoing transformation toward higher-grade malignancy. Within these specimens, SPEAR detected a coordinated decrease in multiple methylated RNA modifications in the higher-grade regions. The authors report that the pattern recurred across patients despite genetic differences among tumours, while bulk analysis masked the localised signal.
The finding makes spatial measurement relevant to studying tumour variation within a specimen: a tissue-wide average may not capture molecular differences between neighbouring regions. The authors propose SPEAR as a platform for biomarker discovery and molecular stratification based on where RNA modifications occur in tissue. Those are potential research uses; the preprint reports a profiling method and regional molecular patterns, not a validated clinical test.
The work is posted as a bioRxiv preprint. The supplied abstract does not give sample counts or effect sizes, so the scale and strength of the reported patient-level pattern cannot be assessed from that information alone.